Press release
Pneumococcal Pneumonia Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Vaxcyte, Merck, Affinivax, GlaxoSmithKline, Pfizer, Eu Biologics
"Pneumococcal Pneumonia Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Pneumococcal Pneumonia Therapeutics Market.
The report provides a detailed description of the Pneumococcal Pneumonia drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Pneumococcal Pneumonia Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/pneumonia-pneumococcal-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Pneumococcal Pneumonia Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Pneumococcal Pneumonia therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pneumococcal Pneumonia treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Pneumococcal Pneumonia drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Pneumococcal Pneumonia treatment market.
Learn More about the Clinical and Commercial Development Activities in the Pneumococcal Pneumonia Therapeutics Domain @
https://www.delveinsight.com/report-store/pneumonia-pneumococcal-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Pneumococcal Pneumonia Therapeutics Analysis
There are approx. 12+ key companies developing therapies for Pneumococcal Pneumonia. Currently, Merck & Co. is leading the therapeutics market with its Pneumococcal drug candidates in the most advanced stage of clinical development.
Pneumococcal Pneumonia Companies in the Therapeutics Market Include:
• Vaxcyte
• Merck & Co
• Affinivax
• GlaxoSmithKline
• Pfizer
• Eu Biologics
And Many Others
Emerging and Marketed Pneumococcal Pneumonia Therapies Covered in the Report Include:
• V116: Merck & Co
V116, the company's investigational 21-valent pneumococcal conjugate vaccine, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A/C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B/C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, 35B in adults 18 years of age and older.
V116 is designed to specifically target serotypes that are responsible for 85 percent of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 20191. Importantly, the eight stereotypes in V116 that are not included in any currently licensed pneumococcal vaccine account for over 30 percent of this disease burden alone.
Get an in-depth Assessment of the Emerging Therapies and Pneumococcal Pneumonia Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/pneumonia-pneumococcal-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Pneumococcal Pneumonia Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates
Route of Administration
Pneumonia, Pneumococcal pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride
Request for Sample PDF to Understand More About the Pneumococcal Pneumonia Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/pneumonia-pneumococcal-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Pneumococcal Pneumonia Current Treatment Patterns
4. Pneumococcal Pneumonia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Pneumococcal Pneumonia Late-Stage Products (Phase-III)
7. Pneumococcal Pneumonia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Pneumococcal Pneumonia Discontinued Products
13. Pneumococcal Pneumonia Product Profiles
14. Pneumococcal Pneumonia Companies
15. Pneumococcal Pneumonia Drugs
16. Dormant and Discontinued Products
17. Pneumococcal Pneumonia Unmet Needs
18. Pneumococcal Pneumonia Future Perspectives
19. Pneumococcal Pneumonia Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/pneumonia-pneumococcal-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pneumococcal Pneumonia Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Vaxcyte, Merck, Affinivax, GlaxoSmithKline, Pfizer, Eu Biologics here
News-ID: 3345829 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Pneumococcal
Key Influencer in the Pneumococcal Vaccine Market 2025: Rising Prevalence Of Pne …
What combination of drivers is leading to accelerated growth in the pneumococcal vaccine market?
The escalating occurrence of pneumococcal infections is projected to boost the pneumococcal vaccine market's growth. Pneumococcal infections represent any condition triggered by the bacterium Streptococcus pneumoniae, also known as pneumococcus. This includes illnesses like pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine encourages the body to generate antibodies against these bacteria, thereby minimizing or…
Pneumococcal Vaccine Market to see Huge Growth by 2029
The global pneumococcal vaccine market is anticipated to grow at a significant CAGR during the forecast period. The major factor for the growth of the market includes the increasing efforts to curb pneumonia among children in developed countries. Whereas, in the developing countries, the increasing spending on infrastructure and rising awareness towards vaccines, are the factors, which are expected to fuel the market growth during the forecasted period.
According to the…
Pneumococcal Vaccines Market - Preventing Pneumonia: Safeguarding Health with Pn …
Newark, New Castle, USA: The "Pneumococcal Vaccines Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Pneumococcal Vaccines Market: https://www.growthplusreports.com/report/pneumococcal-vaccines-market/7761
This latest report researches the industry structure, sales, revenue,…
Global To Invigorate The Intravenous Pneumococcal Vaccines Market
Pneumococcal vaccine is used to prevent infection caused by streptococcus pneumoniae bacteria. There are two types of pneumococcal vaccines: pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine.
The Centers for Disease Control and Prevention (CDC) recommends pneumococcal conjugate vaccine for all children younger than two years of age, all adults 65 years or older, and for people 2-64 years old with certain medical conditions. The CDC recommends pneumococcal polysaccharide vaccine for all…
Pneumococcal Vaccines Market Demands and Gross Margin 2027
"Industry analysis is a crucial step in the current competitive market space that helps identify the right target customers and accordingly provide tailored solutions for their business needs. Every aspect and unique challenges put up by the particular industry are carefully taken into consideration while formulating these solutions. It also takes into consideration various government reforms, competitive environment, customer behavior, existing and upcoming business models, and ever-evolving technological developments. Industry…
Pneumococcal Vaccine Report on Global Pneumococcal Vaccine Market Development, p …
Latest Survey on Pneumococcal Vaccine Market:
The Global Pneumococcal Vaccine market report value has been estimated considering the application and regional segments, market share, and size, while the forecast for each product type and application segment has been provided for the global markets. The Pneumococcal Vaccine report offers detailed profiles of the key players to bring out a clear view of the competitive landscape of the Pneumococcal Vaccine Outlook. It also…
